Seeking Alpha

More on Merck Q1: Net profit +7%

  • Merck (MRK) net profit rises to $1.705B from $1.59B a year earlier
  • Revenues hurt by patent expirations and currency fluctuations.
  • Pharmaceuticals revenues -4.7% to $8.45B, dragged down by generic competition for Merck's Singulair treatment for allergy and asthma; consumer care -4.4%; animal-health -3.2%.
  • Sales of Remicade, Simponi and Isentress, as well as of Diabetes and Vaccines Franchises, grew.
  • Affirms FY guidance for adjusted EPS of $3.35-3.53 vs consensus of $3.45.
  • Shares +1.45% premarket. (PR)
  • Previous
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|